title: Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.
abstract: BACKGROUND
  This study analyzes the prevalence of hospital and community-acquired infections caused by Escherichia coli.
  
  
  METHODS
  The antibiotic resistance pattern was used to characterize the isolates, and a retrospective observational study was performed to assess the relationship between antimicrobial use and bacterial resistance. The study was conducted during a 1-year and 7-month period in a 1,500-bed tertiary care hospital in Anhui, China.
  
  
  RESULTS
  An E. coli infection was diagnosed in 1.4% of patients (519/36,179) admitted to the hospital between March 1, 1999 and August 31, 2000. Of the 519 isolates, 489 (94.2%) were resistant to at least one antimicrobial; 86% were resistant to ampicillin, 85% to cephalothin, 83% to piperacillin, 77% to ampicillin/sulbactam, 72% to trimethoprim/sulfamethoxazole (TMP-SMZ), 70% to ciprofloxacin, 61% to cefoperazone, 58% to tobramycin, 56% to gentamicin, 48% to ticarcillin-clavulanate, 44% to cefazolin, 43% to cefuroxime, 36% to cefoxitin, 32% to cefepime, 29% to aztreonam, cefetaxime and ceftriaxone, 28% to ceftazidime, 19% to piperacillin/tazobactam, 10% to amikacin, while all strains tested were susceptible to imipenem.
  
  
  CONCLUSIONS
  Prior receipt of amtimicrobial therapy was significantly associated with infection caused by a resistant organism.
authors.affiliation: Dept. of Infectious Diseases, First Affiliated Hospital, College of Medical Science, Zhejiang University, China. ljbn2000@sina.com
authors.forename: J B
authors.initials: JB
authors.lastname: Li
authors.forename: Y S
authors.initials: YS
authors.lastname: Yu
authors.forename: Y L
authors.initials: YL
authors.lastname: Ma
authors.forename: W L
authors.initials: WL
authors.lastname: Zhou
authors.forename: X Z
authors.initials: XZ
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D017714:Community-Acquired Infections / Q000453:epidemiology / Q000382:microbiology; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000302:isolation & purification*; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents